Debra Feldman - Dyne Therapeutics Chief Officer
| DYN Stock | USD 31.13 1.90 6.50% |
Executive
Debra Feldman is Chief Officer of Dyne Therapeutics
| Age | 53 |
| Address | 1560 Trapelo Road, Waltham, MA, United States, 02451 |
| Phone | 781 786 8230 |
| Web | https://www.dyne-tx.com |
Dyne Therapeutics Management Efficiency
The company has Return on Asset of (0.4035) % which means that on every $100 spent on assets, it lost $0.4035. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.6868) %, meaning that it generated no profit with money invested by stockholders. Dyne Therapeutics' management efficiency ratios could be used to measure how well Dyne Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 28th of November 2024, Return On Tangible Assets is likely to grow to -1.36. In addition to that, Return On Capital Employed is likely to grow to -2.02. As of the 28th of November 2024, Debt To Assets is likely to grow to 0.26, while Total Assets are likely to drop about 156.8 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Diane Weiser | Cytokinetics | N/A | |
| David MD | Mineralys Therapeutics, Common | 69 | |
| Jan Smith | Revolution Medicines | N/A | |
| Robert Shoemaker | Erasca Inc | 43 | |
| Scott Jordan | Cytokinetics | N/A | |
| Matt Yang | Cytokinetics | N/A | |
| Jeff Lotz | Cytokinetics | N/A | |
| Xiaolin Wang | Revolution Medicines | 53 | |
| Robert McKean | Mineralys Therapeutics, Common | N/A | |
| Huw Nash | Stoke Therapeutics | 57 | |
| Andrew Callos | Cytokinetics | 55 | |
| Jeffrey Fellows | Mineralys Therapeutics, Common | N/A | |
| Elizabeth Gordon | Design Therapeutics | N/A | |
| Kevin Johnston | Cullinan Oncology LLC | N/A | |
| Sarah Foster | Mineralys Therapeutics, Common | N/A | |
| Jason Hoitt | Stoke Therapeutics | 46 | |
| Mary CPA | Cullinan Oncology LLC | 60 | |
| Michael Varney | Erasca Inc | 66 | |
| Thomas Leggett | Stoke Therapeutics | 47 | |
| Rose Weldon | Cullinan Oncology LLC | N/A | |
| MD FACC | Design Therapeutics | 55 | |
Management Performance
| Return On Equity | -0.69 | ||||
| Return On Asset | -0.4 |
Dyne Therapeutics Leadership Team
Elected by the shareholders, the Dyne Therapeutics' board of directors comprises two types of representatives: Dyne Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Dyne. The board's role is to monitor Dyne Therapeutics' management team and ensure that shareholders' interests are well served. Dyne Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Dyne Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Romesh Subramanian, CoFounder Advisor | ||
| Richard MBA, Senior Administration | ||
| Ashish MBA, Chief Officer | ||
| Oxana Beskrovnaya, Chief Officer | ||
| Johanna FriedlNaderer, Chief Officer | ||
| Joshua Brumm, President CEO | ||
| Lucia Celona, Chief Officer | ||
| Daniel Wilson, Senior Legal | ||
| Susanna MBA, Chief Officer | ||
| MS MD, VP Pharmacovigilance | ||
| Debra Feldman, Chief Officer | ||
| John MBA, Chief Officer | ||
| Kate Mitchell, VP Resources | ||
| Gene Kim, VP Fin | ||
| Amy Reilly, Senior Relations | ||
| Jonathan MD, Chief Officer |
Dyne Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Dyne Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.69 | ||||
| Return On Asset | -0.4 | ||||
| Current Valuation | 2.28 B | ||||
| Shares Outstanding | 101.77 M | ||||
| Shares Owned By Insiders | 0.48 % | ||||
| Shares Owned By Institutions | 99.52 % | ||||
| Number Of Shares Shorted | 10.15 M | ||||
| Price To Earning | 35.58 X | ||||
| Price To Book | 4.22 X | ||||
| EBITDA | (233.48 M) |
Pair Trading with Dyne Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Dyne Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dyne Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Dyne Stock
| 0.7 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
Moving against Dyne Stock
| 0.62 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.58 | PHVS | Pharvaris BV | PairCorr |
| 0.53 | NAMS | NewAmsterdam Pharma | PairCorr |
| 0.36 | PMVP | Pmv Pharmaceuticals | PairCorr |
| 0.32 | MNOV | MediciNova | PairCorr |
The ability to find closely correlated positions to Dyne Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Dyne Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Dyne Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Dyne Therapeutics to buy it.
The correlation of Dyne Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Dyne Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Dyne Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Dyne Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dyne Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. To learn how to invest in Dyne Stock, please use our How to Invest in Dyne Therapeutics guide.You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dyne Therapeutics. If investors know Dyne will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dyne Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.58) | Return On Assets (0.40) | Return On Equity (0.69) |
The market value of Dyne Therapeutics is measured differently than its book value, which is the value of Dyne that is recorded on the company's balance sheet. Investors also form their own opinion of Dyne Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dyne Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dyne Therapeutics' market value can be influenced by many factors that don't directly affect Dyne Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dyne Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dyne Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dyne Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.